Treatment of Frontal-Predominant Alzheimer's Disease
Cholinesterase inhibitors and memantine should NOT be used for frontal-predominant Alzheimer's disease, as these medications lack evidence of benefit in this atypical AD variant and guidelines explicitly recommend against their use in non-typical AD presentations.
Key Recommendation
The 2020 Canadian Consensus Conference on Dementia provides the clearest guidance: cholinesterase inhibitors (ChEIs) should be discontinued in individuals prescribed these medications for indications other than typical AD, Parkinson's disease dementia, Lewy body dementia, or vascular dementia 1. Frontal-predominant AD (fvAD) is specifically mentioned as an example where ChEIs should be discontinued (Level 1B recommendation, 93% consensus) 1.
Similarly, memantine should be discontinued for indications other than typical AD, PDD, DLB, or VD, with frontotemporal dementia and other neurodegenerative conditions (which would include fvAD) specifically cited as examples (Level 1C recommendation, 91% consensus) 1.
Clinical Context and Diagnostic Considerations
Frontal variant AD presents a significant diagnostic challenge because it mimics behavioral variant frontotemporal dementia (bvFTD) with:
- Executive dysfunction as the predominant feature
- Personality and behavioral changes
- Relative sparing of memory initially
- Asymmetric frontal and temporal atrophy on imaging 2
The critical distinction is that fvAD shows underlying Alzheimer's pathology (amyloid plaques and tau tangles) despite the atypical clinical presentation. Accurate diagnosis requires:
- Biomarker confirmation: Elevated CSF or plasma phospho-tau and decreased Aβ42/40 ratio 2, 3
- Amyloid PET imaging: Though some cases may show low or equivocal amyloid retention 3
- Tau PET imaging: AD-specific tau tracers (like 18F-MK6240) can be particularly valuable when amyloid PET is equivocal, showing increased retention in frontal regions 3
Treatment Approach
What NOT to Do
- Do not prescribe standard AD medications (donepezil, rivastigmine, galantamine, memantine) for fvAD
- These drugs are approved and effective only for typical amnestic AD presentations 1
Emerging Disease-Modifying Therapies
While traditional symptomatic treatments are not recommended, anti-amyloid monoclonal antibodies (lecanemab, donanemab) may be considered if the patient meets criteria for early-stage AD with confirmed amyloid pathology 4, 5. However:
- These require biomarker-confirmed diagnosis
- Extensive safety monitoring is mandatory (scheduled MRI for amyloid-related imaging abnormalities)
- Evidence specifically in fvAD is limited
- They are approved for early-stage disease, not advanced presentations
Symptomatic Management
Focus treatment on:
- Behavioral symptoms: If agitation is present, brexpiprazole is FDA-approved for agitation in AD 5, 6
- Sleep disturbances: Suvorexant for insomnia 5, 6
- Non-pharmacological interventions: Cognitive training, caregiver support, case management 1
Important Caveats
If a patient with fvAD is already on ChEIs or memantine, deprescribing should be done gradually:
- Reduce dose by 50% every 4 weeks until reaching the initial starting dose
- After 4 weeks at starting dose, discontinue completely
- Monitor for worsening; reinitiate if clinically meaningful decline occurs related to cessation 1
Exception: Do not discontinue ChEIs if the patient currently has clinically meaningful psychotic symptoms, agitation, or aggression until these stabilize 1.
The fundamental issue is that fvAD represents a distinct clinical-pathological entity where the standard symptomatic treatments for typical AD have not demonstrated benefit, and guidelines explicitly recommend against their use in this population.